Case 1: Seventy-five percent of women older than 50 years will experience vasomotor symptoms (VMSs) such as hot flashes and night sweats. Many FDA-approved medications are available for treating VMSs, and most contain estrogen alone or in combination with a progestin. The American Association of Clinical Endocrinologists, American College of Obstetricians and Gynecologists, and the North American Menopause Society recommend hormone replacement therapy (HRT) prescribed at the lowest effective dose and for the shortest duration possible in women for whom the benefits outweigh the risks.
HRT is the most effective and well-studied treatment option for VMSs; however, due to DG’s history of breast cancer, it is contraindicated. Therefore, nonhormonal therapies and/or lifestyle changes are an appropriate treatment option for relief of DG’s VMSs. In June 2013, the FDA approved paroxetine (Brisdelle) 7.5 mg once daily at bedtime as the first nonhormonal treatment option for VMSs.
Lifestyle changes are also recommended for all women with VMSs associated with menopause. Women should be encouraged to wear loose-fitting, lightweight, cotton clothing; avoid hot foods and drinks; and dress in layers to regulate their core body temperature. Regular physical activity, relaxation techniques, weight loss, and smoking cessation have also been effective in alleviating VMSs.
Case 2: Malaria is caused by 1 of 4 protozoan species transmitted by the bite of an infected mosquito. The risk of acquiring malaria depends on the region, season, and type of travel. Travelers with a high risk of infection should receive prophylaxis and use mosquito-avoidance measures such as remaining in well-screened areas, using mosquito nets, wearing protective clothing, and using effective insecticide spray.
Six chemoprophylaxis agents are currently available for malaria prophylaxis: atovaquone/ proguanil, chloroquine phosphate, hydroxychloroquine sulfate, doxycycline, mefloquine, and primaquine. All recommended agents involve the patient taking the medication before, during, and after travel to malaria-endemic areas. Each medication comes with its own dosing regimen, duration, and side effects, which should be considered when choosing an agent. The Centers for Disease Control and Prevention has a list of the recommended drugs and the comparable efficacy of each agent in every country (http://phrmcyt.ms/1eUKpYv), which can help in deciding which malaria prevention medication to use.
Atovaquone/proguanil (Malarone) is the agent most commonly associated with vivid dreams. Because chloroquine phosphate, hydroxychloroquine sulfate, and mefloquine require treatment to be started at least 1 week prior to arrival in the endemic area, they are not options for LH. If LH will not take atovaquone/proguanil because of the potential for vivid dreams, doxycycline or primaquine is the remaining option because prophylaxis with either agent should begin 1 or 2 days before travel to malarious areas. Patients who are going to take primaquine should have a documented normal G6PD level before starting the medication. For this reason, doxycycline administered as 1 tablet daily, beginning 1 or 2 days before travel, and continued for 4 weeks after travel may be the best choice.
While many states across our nation are engaged in political battles over the recreational use of marijuana, researchers have been busy studying the medical benefits of cannabidiol.
News from the year's biggest meetings
Clinical features with downloadable PDFs